Pt. Otsuka Indonesia

Pt. Otsuka Indonesia company information, Employees & Contact Information

Updated May 2026

Quick answer

Pt. Otsuka Indonesia is a Pharmaceutical Manufacturing company and founded in 1975. It has approximately 686 employees on record. Contact data was last refreshed in May 2026. Find Pt. Otsuka Indonesia's verified employee emails, phone numbers, headquarters address, and key decision makers below.

PT Otsuka Indonesia was established in 1974 as a joint venture pharmaceutical company with Otsuka Pharmaceutical Co., Ltd., Japan. PT Otsuka Indonesia manufactures and promotes 4 (four) product groups, namely: Therapeutics Drug, Clinical Nutrition and I.V. Solution, Medical Devices, IV SET. As for now, our Head Office is in South Jakarta and our Factory is build over a land area of around 40.000 square meters at Lawang, East Java. For decades, PT Otsuka Indonesia has proved itself as the leader in the Infusion Solutions business. And to strengthen our position, we keep challenging ourselves to develop new products that will fulfill customer needs in the future, based on our motto: “Otsuka People Creating New Products for Better Health Worldwide". Follow our social media to know more about us: Instagram : @Otsuka.Indonesia For career information please visit our website : www.otsuka.co.id

Company Details

Employees
686
Founded
1975
Address
Pondok Indah Office Tower 1, Lantai 8, Jalan Sultan Iskandar Muda Kav. V-Ta, Jakarta Selatan,dki Jakarta 12310,indonesia
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Jakarta Selatan, DKI Jakarta
Looking for a particular Pt. Otsuka Indonesia employee's phone or email?

Pt. Otsuka Indonesia Questions

News

Launch of AR-Based Nutrition Education Game App, "Mogumogu Town"Collect "Mogumin" Food Characters and Build Your Town|February 19, 2024|News Releases | Otsuka Pharmaceutical Co., Ltd. - otsuka.co.jp

Launch of AR-Based Nutrition Education Game App, "Mogumogu Town"Collect "Mogumin" Food Characters and Build Your Town|February 19, 2024|News Releases | Otsuka Pharmaceutical Co., Ltd. otsuka.co.jp

Otsuka America, Inc’s. Data and Technology Company will Support Rejoyn™ Commercialization & Personalized Patient Engagement - Business Wire

Otsuka America, Inc’s. Data and Technology Company will Support Rejoyn™ Commercialization & Personalized Patient Engagement Business Wire

Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. - GlobeNewswire

Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. GlobeNewswire

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka - citybiz

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka citybiz

A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels - statnews.com

A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels statnews.com

Otsuka Pharmaceutical Co.,Ltd. - otsuka.co.jp

Otsuka Pharmaceutical Co.,Ltd. otsuka.co.jp

Otsuka Precision Health, Inc. (OPH) and Amalgam Rx Announce the Digital Support Solution for Caregivers Supporting Patients with Alzheimer’s Disease - Business Wire

Otsuka Precision Health, Inc. (OPH) and Amalgam Rx Announce the Digital Support Solution for Caregivers Supporting Patients with Alzheimer’s Disease Business Wire

Otsuka Pharmaceutical Co.,Ltd. - otsuka.co.jp

Otsuka Pharmaceutical Co.,Ltd. otsuka.co.jp

Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms - Business Wire

Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms Business Wire

Otsuka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-|August 11, 2020|News Releases | Otsuka Pharmaceutical Co., Ltd. - otsuka.co.jp

Otsuka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-|August 11, 2020|News Releases | Otsuka Pharmaceutical Co., Ltd. otsuka.co.jp

Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD) - Business Wire

Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD) Business Wire

Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit - Minimum detection sensitivity improved compared to QuickNaviTM-Noro2 -|September 28, 2022|News Releases | Otsuka Pharmaceutical Co., Ltd. - otsuka.co.jp

Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit - Minimum detection sensitivity improved compared to QuickNaviTM-Noro2 -|September 28, 2022|News Releases | Otsuka Pharmaceutical Co., Ltd. otsuka.co.jp

Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration - Business Wire

Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration Business Wire

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults - Business Wire

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults Business Wire

Otsuka and Lundbeck Announce FDA Acceptance of Supplemental New Drug Application; Receive Priority Review for Treatment of Schizophrenia in Adolescents - Business Wire

Otsuka and Lundbeck Announce FDA Acceptance of Supplemental New Drug Application; Receive Priority Review for Treatment of Schizophrenia in Adolescents Business Wire

Top Pt. Otsuka Indonesia Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant